Immix Biopharma (IMMX) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Immix Biopharma (NASDAQ: IMMX) in the last few weeks:

• 10/29/2026 – Immix Biopharma was given a new $23.00 price target by Mizuho.
• 10/20/2026 – Immix Biopharma had its “overweight” rating reaffirmed by Morgan Stanley.
• 10/20/2026 – Immix Biopharma was given a new $20.00 price target by Morgan Stanley.
• 10/15/2026 – Immix Biopharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/30/2026 – Immix Biopharma had its “market outperform” rating reaffirmed by Citigroup.
• 9/29/2026 – Immix Biopharma had its price target raised by Needham & Company LLC from $21.00 to $30.00. They now have a “buy” rating on the stock.
• 9/15/2026 – Immix Biopharma had its price target raised by Mizuho from $15.00 to $26.00. They now have an “outperform” rating on the stock.

Immix Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with difficult-to-treat cancers and other serious diseases. The company’s research and development activities are centered on engineered immune-cell treatments intended to target malignant cells.

Its lead product candidate is NXC-201, an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target B-cell maturation antigen (BCMA). NXC-201 is being evaluated in clinical studies for relapsed or refractory multiple myeloma and relapsed or refractory AL amyloidosis, a rare blood disorder in which abnormal plasma cells produce misfolded proteins.

Immix Biopharma was founded in 2012 and is headquartered in Los Angeles, California.

Read More

• Five stocks we like better than Immix Biopharma
• Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
• NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
• GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
• Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?

Receive News & Ratings for Immix Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.